Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
gptkb:peginterferon_alfa-2b
|
| gptkbp:approvalYear |
2001
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:L03AB10
|
| gptkbp:chemicalClass |
gptkb:insulin
|
| gptkbp:combinationTherapy |
ribavirin
|
| gptkbp:contraindication |
autoimmune hepatitis
decompensated liver disease |
| gptkbp:discontinued |
some markets
|
| gptkbp:eliminatedIn |
renal
|
| gptkbp:form |
powder for solution
|
| gptkbp:halfLife |
40 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
PEG-INTRON
|
| gptkbp:indication |
gptkb:chronic_hepatitis_C
chronic hepatitis B (off-label) |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:mechanismOfAction |
immunotherapy
antiviral |
| gptkbp:pegylated |
true
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
gptkb:depression
gptkb:anemia fatigue neutropenia flu-like symptoms |
| gptkbp:usedFor |
gptkb:hepatitis_C
|
| gptkbp:bfsParent |
gptkb:MRK
|
| gptkbp:bfsLayer |
5
|